- Provides readers with access to a range of information from the basic mechanisms and assays to cutting-edge research investigating concerns for human health- Presents a comprehensive, translational look at all aspects of endocrine disruption and its effects on human health- Offers guidance on the risk assessment of endocrine disruptors and current relevant regulatory considerations
OVERVIEW and SCOPE 1. What is endocrine disruption? 2. Which chemicals are endocrine disruptors? SECTION 2
MECHANISMS and ASSAY SYSTEMS 3. Environmental oestrogens: disrupters of oestrogen action 4. Disrupters of androgen action 5. Assay systems for studying endocrine disruption 6. Non-monotonic responses in endocrine disruption 7. Endocrine disrupters as modifiers of endogenous hormone synthesis SECTION 3
CONCERNS FOR HUMAN HEALTH 8. Endocrine disruption and female reproductive health 9. Endocrine disruption and breast cancer 10. Endocrine disruption and male reproductive health 11. Endocrine disruption and prostate cancer 12. Endocrine disruption and thyroid disease 13. Endocrine disruption of adrenal function 14. Endocrine disruption of developmental pathways and children's health 15. Endocrine disruption of immune function 16. Endocrine disruption and obesity, metabolic syndrome and type 2 diabetes 17. Endocrine disruption and cardiovascular disease 18. Transgenerational effects of endocrine disruption 19. Regulatory considerations
Dr Philippa Darbre is Associate Professor in Oncology in the School of Biological Sciences at the University of Reading in the UK. She is an academic scientist who has been carrying out research into estrogen action in breast cancer for over 30 years and has been investigating the role of estrogen-mimicking chemicals since before the term "endocrine disruption came into being in the early 1990s. She trained as a biochemist and holds the degrees of BScHons from the University of Birmingham, UK (1973) and PhD from the University of Cambridge, UK (1977). Her postdoctoral research began at the Molecular Medicine Institute at the University of Oxford where she held the first Nuffield Medical Research Fellowship of the University of Oxford and a Junior Research Fellowship at St Hugh's College. In 1981, she moved to the Imperial Cancer Research Fund laboratories in central London (now Cancer Research UK) where she became Head of the Cellular Endocrinology Laboratory. In 1991, she moved to the University of Reading where she has completed now 23 years of service carrying our research focused on breast cancer and engaging in undergraduate teaching in the areas of biochemistry, molecular cell biology, endocrinology and cancer. She is currently programme advisor for the undergraduate biochemistry degree programme and has four overseas postgraduate PhD students. She is on the editorial board of two scientific journals, has written two previous books on molecular biology methods, has guest-edited a previous journal volume on endocrine disrupters and has published over 120 peer-reviewed research papers. She is a patron of the charity CancerActive, is a member of the pool of scientific advisors to the European Union Scientific Risk Assessment Advisory Committee on Health and Environmental Risks, and is a member of the scientific advisory board of the Halifax project (Canada) on environmental long-term low-dose mixtures and cancer.